This article has been updated to include news of a court award to CombiMatrix and a stock quote.
 
NEW YORK (GenomeWeb News) – CombiMatrix today reported that its fourth-quarter revenues more than doubled and the firm cut its net loss 22.2 percent as it continued its transition to focusing on molecular diagnostics.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.